Evidence map›Paper›PMID 40991084›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

β2-Microglobulin: A potential novel prognostic indicator for neuroblastoma.

Yan Lei, Jianjun Zhu, Xiaoning Liu, Yuantao Zhou, Li Li

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan Lei *Kunming Medical University, No. 1168 Chunrong West Road, Yuhua Street, Chenggong District, Kunming, 650500, Yunnan, China.
Jianjun Zhu *Department of Oncology, Kunming Children's Hospital, No. 288 Qianxing Road, Xishan District, Kunming, 650228, Yunnan, China.
Xiaoning Liu *Department of Pharmacy, Kunming Children's Hospital, No. 288 Qianxing Road, Xishan District, Kunming, 650228, Yunnan, China.
Yuantao ZhouKunming Medical University, No. 1168 Chunrong West Road, Yuhua Street, Chenggong District, Kunming, 650500, Yunnan, China.
Li LiKunming Medical University, No. 1168 Chunrong West Road, Yuhua Street, Chenggong District, Kunming, 650500, Yunnan, China. lily20020302@hotmail.com.ORCID http://orcid.org/0009-0004-7487-5640

Funding

Applied Basic Research Key Project of Yunnan 202401AS070008Cultivating Plan Program for the Leader in Science and Technology of Yunnan Province 202105AC160012Medical Science and Technology Project of Zhejiang Province 202201AY070001-206National Natural Science Foundation of China 81960294unnan Provincial Health and Health Commission Medical High-end Talent Training Program L-2024021
6 · The paper itself

Abstract

backgroundNeuroblastoma is a prevalent malignant tumor in children, with significant challenges in prognosis assessment. This study investigated the potential value of β2-microglobulin for predicting outcomes in patients with intermediate- to high-risk neuroblastoma.

methodsWe conducted a retrospective analysis of 40 patients with intermediate- to high-risk NB treated at the Children's Hospital of Kunming Medical University from 2018-2021. Peripheral blood and tissue samples were collected, and relevant biomarkers were detected via flow cytometry and real-time quantitative PCR (RT-qPCR).

resultsβ2-microglobulin was the only biomarker significantly associated with NB prognosis. Patients in the high-expression group had a significantly greater three-year survival rate than those in the low-expression group (P < 0.01). Logistic regression analysis, combined with clinical data and receiver operating characteristic curves, indicated that β2-microglobulin had predictive capabilities comparable to those of neuron-specific enolase, suggesting its potential role in treatment assessment and prognostic evaluation.

conclusionβ2-microglobulin has significant prognostic value in intermediate- to high-risk neuroblastoma patients and may serve as an effective biomarker for clinical prognosis. These findings offer new insights for individualized neuroblastoma treatment, emphasizing the need for future research on its applicability in diverse populations and potential use in treatment monitoring.

Indexed as

beta 2-MicroglobulinBiomarkers, TumorNeuroblastomaChildChild, PreschoolFemaleHumansInfantMalePrognosisRetrospective StudiesB2M protein, humanbeta 2-MicroglobulinBiomarkers, TumorBiomarkersNeuroblastomaNSEPrognostic biomarkerβ2-microglobulin

Identifiers

PMID40991084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.